- Home
- NAN vs CLLS Comparison
NAN vs CLLS Comparison
Compare NAN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAN
- CLLS
- Stock Information
- Founded
- NAN 1999
- CLLS 1999
- Country
- NAN United States
- CLLS France
- Employees
- NAN N/A
- CLLS N/A
- Industry
- NAN Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NAN Finance
- CLLS Health Care
- Exchange
- NAN Nasdaq
- CLLS Nasdaq
- Market Cap
- NAN 337.8M
- CLLS 299.0M
- IPO Year
- NAN N/A
- CLLS 2007
- Fundamental
- Price
- NAN $11.52
- CLLS $3.15
- Analyst Decision
- NAN
- CLLS Buy
- Analyst Count
- NAN 0
- CLLS 1
- Target Price
- NAN N/A
- CLLS $4.00
- AVG Volume (30 Days)
- NAN 74.6K
- CLLS 76.4K
- Earning Date
- NAN 01-01-0001
- CLLS 11-03-2025
- Dividend Yield
- NAN 4.37%
- CLLS N/A
- EPS Growth
- NAN N/A
- CLLS N/A
- EPS
- NAN N/A
- CLLS N/A
- Revenue
- NAN N/A
- CLLS $63,438,000.00
- Revenue This Year
- NAN N/A
- CLLS N/A
- Revenue Next Year
- NAN N/A
- CLLS $66.76
- P/E Ratio
- NAN N/A
- CLLS N/A
- Revenue Growth
- NAN N/A
- CLLS 223.09
- 52 Week Low
- NAN $9.11
- CLLS $1.10
- 52 Week High
- NAN $11.34
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- NAN 54.35
- CLLS 54.47
- Support Level
- NAN $10.90
- CLLS N/A
- Resistance Level
- NAN $11.60
- CLLS $3.35
- Average True Range (ATR)
- NAN 0.06
- CLLS 0.15
- MACD
- NAN -0.56
- CLLS -0.09
- Stochastic Oscillator
- NAN 99.28
- CLLS 94.03
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.